DNLI Denali Therapeutics
Denali Therapeutics earnings company data as of 3:06 PM ET 10/30
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Nov | EPS | -0.37 | — | — |
| Rev | $22.9M | — | — |
Insider trades
Open-market buys and sales by DNLI's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $327K sold by 2 insiders under 10b5-1 plans
-
Nancy Thornberry DirectorPlanned sale$262K 11,439 shares at $22.90 37% of stakeTraded Sep 2 Filed Sep 4
-
Alexander O. Schuth COFO and SecretaryPlanned sale$65K 2,768 shares at $23.44 1% of stakeTraded Sep 1 Filed Sep 3
Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 4 sales to cover taxes, and 1 gift.
SEC filings
Recent issuer filings from EDGAR, 22 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | DEFA14A ADDITIONAL MATERIALS | Filing Doc | |
| 8-K | 1.02,9.01 | Filing Doc | |
| 8-K | 2.03,7.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 1.01,8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.